Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements after neuroleptic dose

J W Newcomer1, S J Riney, S Vinogradov

  • 1Department of Psychiatry, Washington University School of Medicine, St. Louis, MO 63110.

Psychopharmacology Bulletin
|January 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Validated Tropical-Extratropical Flood Hazard Assessment for New York Harbor.

Journal of geophysical research. Oceans·2019
Same author

Getting to precision psychopharmacology: Combining clinical and genetic information to predict fat gain from aripiprazole.

Journal of psychiatric research·2019
Same author

SU-E-I-94: External Beam Radiation Cherenkov Emission in Tissue Used for Tissue Oxygen Sensing.

Medical physics·2017
Same author

Intranasal oxytocin increases facial expressivity, but not ratings of trustworthiness, in patients with schizophrenia and healthy controls.

Psychological medicine·2017
Same author

Corticotropin-releasing factor overexpression gives rise to sex differences in Alzheimer's disease-related signaling.

Molecular psychiatry·2016
Same author

Oxytocin administration selectively improves olfactory detection thresholds for lyral in patients with schizophrenia.

Psychoneuroendocrinology·2015

Plasma prolactin (pPRL) and homovanillic acid (pHVA) levels in schizophrenia patients did not predict symptom changes after haloperidol dose reduction. Baseline pPRL correlated with symptoms, but this link weakened with dose changes.

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Schizophrenia treatment often involves dopamine-blocking antipsychotics like haloperidol.
  • Biomarkers such as plasma prolactin (pPRL) and homovanillic acid (pHVA) are explored to understand dopamine function during treatment.
  • Tardive dyskinesia (TD) and cognitive deficits are common side effects.

Purpose of the Study:

  • To investigate the relationship between baseline plasma prolactin (pPRL) and plasma homovanillic acid (pHVA) levels and clinical symptoms in male schizophrenia patients on haloperidol.
  • To determine if these neurochemical markers predict clinical changes following a haloperidol dose reduction.

Main Methods:

  • Measurements of pPRL, pHVA, and symptomatology in 24 male schizophrenia patients on maintenance haloperidol.

Related Experiment Videos

  • A subset of 14 patients underwent a 50% haloperidol dose decrease under double-blind, placebo-controlled conditions.
  • Correlational analyses were performed at baseline and after dose reduction.

    • Main Results:

    • At baseline, pPRL showed significant inverse correlations with tardive dyskinesia (TD) and 'thinking disorder', and a direct correlation with negative symptoms.
    • No significant correlations were found between baseline pHVA and any clinical variables.
    • After haloperidol dose decrease, no relationship was observed between baseline pPRL or pHVA and subsequent clinical outcomes.

    Conclusions:

    • Baseline pPRL and pHVA levels do not reliably serve as markers for central dopamine function changes after a haloperidol dose reduction in schizophrenia.
    • The observed baseline correlations between pPRL and symptoms may not predict treatment response or side effect profiles after dose adjustments.